Finally, this elastin degradation and the ensuing EDP release are considered as the aging markers and contribute to cardiovascular diseases such as arterial hypertension, atherosclerosis, and aneurysms (Boutouyrie et al., 2002; Reference Values for Arterial Stiffness C, 2010; Sarafidis et al., 2017) but also contributes to metabolic syndrome development (Blaise et al., 2013; Hocine et al., 2020; Romier et al., 2018). Here, ELN is linked to cardiovascular disorder.